Remedium Lifecare Delivers Strong Q2 Results with Profit Nearly Doubling to Rs.862.34 Lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Ltd (formerly Roxy Exports Limited) reported a strong Q2 FY26, with consolidated profit after tax rising 85.49% sequentially to Rs.862.34 lakh from Rs.464.88 lakh in Q1 FY26. EBITDA also jumped 82.70% to Rs.1,043.69 lakh, and Q2 revenue from operations stood at Rs.11,105.82 lakh with EPS doubling to Rs.0.10. For H1 FY26, PAT reached Rs.1,327.22 lakh versus just Rs.213 lakh for the entire prior fiscal year (FY24-25), highlighting a dramatic turnaround. Total consolidated assets stood at Rs.1,62,318.10 lakh as of September 30, 2025. The company also announced two new board appointments and continues expanding its global footprint via a Singapore subsidiary and growing CDMO capabilities.
Sharp sequential and year-on-year profit growth, with H1 PAT already more than six times the full prior-year PAT, signals a major operational turnaround that is likely to be viewed positively by retail investors. However, the absolute EPS remains very low (Rs.0.10–0.15), and the stock may already reflect much of this momentum; investors should watch for sustained growth in coming quarters.